Global Dyspnea Treatment MarketThe global dyspnea treatment market, valued at USD 5.90 billion in 2022, is expected to experience robust growth, projected to reach approximately USD 12.3 billion by ...

and Hikma and partner Vectura require a further trial to get their drug past the FDA. A trial of AstraZeneca and Avillion's first-in-class asthma rescue inhaler Airsupra has been halted early ...

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading. Riad Mishlawi, Hikma’s CEO, said: “I am pleased ...

PARIS, FRANCE - AUGUST 24: Inhaler performs during the Rock en Seine Festival on August 24, 2024 in Paris, France. (Photo by Kristy Sparow/Getty Images) Inhaler have suggested that they will be ...

(Photo: Company Website) Global pharma major Lupin Limited on Monday announced its focus on formulating respiratory inhalers by incorporating a propellant with near-zero global warming potential ...

Recent research reveals that anti-inflammatory inhalers not only cut the risk of severe asthma complications but also offer modest improvements in symptom control compared to traditional ...

Doctors could be taught to limit the use of traditional asthma inhalers due to their environmental impact. This initiative, led by the University of Glasgow and coordinated by the European ...

Hikma started CohenCare in 2020 with 3 partners after recognizing a significant gap in compassionate home care options in her community. Her desire to create a nurturing environment for those in ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...